Novartis, CH0012005267

Novartis schedules remibrutinib call as Novartis stock costs EUR 138.14

Published on 10/23/2026 at 10:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis holds a remibrutinib update on October 23, 2026. Novartis stock costs EUR 138.14 at Lang & Schwarz ahead of October 27 results.

Upcoming catalysts and results

Novartis has scheduled its remibrutinib investor call for October 23, 2026.
Second-quarter net sales reached USD 14.95 billion, up 3 percent in US dollars.
Novartis stock trades at EUR 138.14 at 10:48 a.m. CEST at Lang & Schwarz on October 23, 2026.

Bauhaus-Grafikposter mit geometrischem Tabletten-Raster in Kobaltblau, Weiß und Mintgrün — Novartis AG CH0012005267 – Bauhaus-Poster mit stilisiertem Tabletten-Raster in Blau, Weiß und Hellgrün, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) was trading at EUR 138.14 at Lang & Schwarz on October 23, 2026 at 10:48 a.m. CEST. The drugmaker scheduled a remibrutinib investor call for the same date, while third-quarter results are due on October 27, 2026, according to Novartis.

Remibrutinib takes center stage

The investor call places remibrutinib at the center of the next company update. Novartis is using the event to discuss the medicine in multiple sclerosis, with the webcast scheduled for October 23, 2026 at 6:30 p.m. EDT, according to the company investor calendar.

The timing gives investors two near-term reference points. The remibrutinib discussion comes first, followed by the third-quarter report on October 27, 2026, before the Swiss market opens. Both dates are listed on the company investor page.

What does the Q2 base show?

Novartis entered the reporting sequence with second-quarter net sales of USD 14.95 billion, up 3 percent in US dollars from the year-earlier period, while net income fell 19 percent to USD 3.26 billion. The figures came from the second-quarter period ended June 30, 2026, as summarized by Ticker Scout.

Core operating income was USD 5.94 billion in the second quarter, unchanged from the prior-year period, with a 41.2 percent core operating margin versus 42.2 percent a year earlier. Kisqali sales rose 43 percent in constant currencies to USD 1.70 billion, while Entresto sales fell 51 percent to USD 1.18 billion.

Upcoming dates frame the next test

The October 23, 2026 remibrutinib call and the October 27, 2026 third-quarter results are the next dated catalysts. Management had reaffirmed full-year 2026 guidance for low-single-digit net-sales growth and a low-single-digit decline in core operating income in constant currencies in the second-quarter update.

Stock price and market value

Novartis also had a market capitalization of USD 297.0 billion and a 52-week range of USD 121.57 to USD 170.46 as of October 22, 2026. Those figures provide a separate US-dollar valuation context for the euro quotation used by German investors.

The stock was trading at EUR 138.14 at Lang & Schwarz on October 23, 2026 at 10:48 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.